Business Context and Reporting Period
This Form 8-K was filed by Lineage Cell Therapeutics, Inc. on June 23, 2025. The report discloses the presentation of 36-month visual acuity results from a Phase 1/2a clinical study of RG6501 (OpRegen) for geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The data was presented at Clinical Trials at the Summit (CTS) 2025 on June 20, 2025.
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial results and regulatory disclosures.
Material Changes and Clinical Results
The filing details sustained efficacy of OpRegen cell therapy in Cohort 4 patients (less advanced GA) through 36 months:
- Visual Acuity: Mean change in Best Corrected Visual Acuity (BCVA) for 10 patients completing 3-year follow-up was +6.2 ETDRS letters (up from +5.5 at 24 months).
- Extensive Coverage Subgroup: In 5 patients with extensive OpRegen bleb coverage, mean BCVA change was +9.0 ETDRS letters (up from +7.4 at 24 months).
- Structural Improvements: Sustained retinal structural improvements were observed in the external limiting membrane (ELM) and RPE drusen complex (RPEDC) layers via Optical Coherence Tomography (OCT).
- Comparison to Untreated Eyes: Treated eyes maintained structural gains, whereas untreated fellow eyes showed continued decline in RPEDC and ELM areas.
Outlook, Risks, and Contingencies
Future Development: The "GAlette" Phase 2a study (NCT05626114) is currently enrolling to evaluate subretinal delivery of OpRegen and test proprietary surgical devices.
Risks and Contingencies:
- Clinical Uncertainty: Positive early findings may not predict success in subsequent studies or regulatory approval.
- Manufacturing Risks: The ongoing Israeli regional conflict may materially impact manufacturing processes, cell banking, and product manufacturing conducted at the subsidiary in Jerusalem.
- Collaboration Dependency: Development is under an exclusive worldwide collaboration with Roche and Genentech; their success in advancing the therapy is critical.
Investor Verification Checklist
- Verify the enrollment status and design of the ongoing "GAlette" Phase 2a study (NCT05626114).
- Assess the specific impact of the Israeli regional conflict on Lineage's manufacturing capabilities in Jerusalem.
- Review the terms of the collaboration agreement with Roche and Genentech regarding milestone payments and development responsibilities.
- Confirm the durability of the +6.2 letter visual acuity gain in the broader patient population beyond the specific Cohort 4 subgroup.